Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Antisense therapy-focused Ionis Pharmaceuticals Inc. announced a pair of licensing deals in recent weeks – with Dynacure SAS and Janssen Biotech Inc. – for candidates developed with its Generation 2.5 chemistry technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?